Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and/or dynamically identify one or more features, such as plaque and vessels, and/or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, and/or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and/or quantified parameters.
1. A computer-implemented method of tracking efficacy of a treatment for a plaque-based disease based on non-invasive medical image analysis, the method comprising:
accessing, by a computer system, a first set of plaque parameters and a first set of vascular parameters associated with a subject, wherein the first set of plaque parameters and the first set of vascular parameters are derived from a first set of medical images of the subject comprising at least one axial image comprising one or more regions of plaque, wherein the first set of medical images of the subject is obtained non-invasively at a first point in time, wherein the first set of plaque parameters comprises density and volume of one or more regions of plaque derived from the first set of medical images of the subject obtained at the first point in time, and wherein the first set of vascular parameters comprises one or more of vascular volume, diameter, area, length, location, or remodeling derived from the first set of medical images of the subject obtained at the first point in time;
generating, by the computer system, a first characterized region of plaque, wherein generating the first characterized region of plaque comprises characterizing the one or more regions of plaque derived from the first set of medical images of the subject obtained at the first point in time as calcified plaque, non-calcified plaque, or low density non-calcified plaque based on the first set of plaque parameters;
accessing, by the computer system, a second set of medical images of the subject, wherein the second set of medical images of the subject is obtained non-invasively at a second point in time after the subject is treated with a treatment, the second point in time being later than the first point in time, wherein the second set of medical images of the subject comprises at least one axial image comprising the one or more regions of plaque;
identifying, by the computer system, the one or more regions of plaque from the second set of medical images;
determining, by the computer system, a second set of plaque parameters and a second set of vascular parameters associated with the subject by analyzing the one or more regions of plaque identified from the second set of medical images, the second set of plaque parameters determined based at least in part on graphical identification of vessel wall and lumen wall from the second set of medical images, wherein the second set of plaque parameters comprises density and volume of the one or more regions of plaque derived from the second set of medical images of the subject obtained at the second point in time, and wherein the second set of vascular parameters comprises one or more of vascular volume, diameter, area, length, location, or remodeling derived from the second set of medical images of the subject obtained at the second point in time;
generating, by the computer system, a second characterized region of plaque, wherein generating the second characterized region of plaque comprises characterizing the one or more regions of plaque derived from the second set of medical images of the subject obtained at the second point in time as calcified plaque, non-calcified plaque, or low density non-calcified plaque based on the second set of plaque parameters;
analyzing, by the computer system, one or more changes between the first characterized region of plaque and the second characterized region of plaque;
analyzing, by the computer system, one or more changes between the first set of vascular parameters and the second set of vascular parameters; and
generating, by the computer system, a graphical representation of tracking progression of the plaque-based disease based at least in part on the analyzed one or more changes between the first characterized region of plaque and the second characterized region of plaque and the analyzed one or more changes between the first set of vascular parameters and the second set of vascular parameters, wherein the generated graphical representation of tracking progression of the plaque-based disease is configured to be used to determine efficacy of the treatment, wherein the determined efficacy of the treatment is configured to be used to determine whether to change the treatment for the subject;
wherein the computer system comprises a computer processor and an electronic storage medium.
2. The computer-implemented method of claim 1 , wherein the graphical representation of tracking progression of the plaque-based disease is generated on one or more of a per-subject, per-vessel, per-segment, or per-lesion basis.
3. The computer-implemented method of claim 1 , wherein the generated graphical representation of tracking progression of the plaque-based disease comprises a representation of one or more of progression, regression, mixed response—progression of calcified plaque, or mixed response—progression of non-calcified plaque.
4. The computer-implemented method of claim 1 , further comprising determining the efficacy of the treatment based at least in part on the progression of the plaque-based disease.
5. The computer-implemented method of claim 4 , further comprising generating a further proposed treatment based at least in part on the determined efficacy of the treatment determined based on the tracked progression of the plaque-based disease.
6. The computer-implemented method of claim 1 , wherein the treatment comprises one or more of a medication treatment, lifestyle treatment, or revascularization treatment.
7. The computer-implemented method of claim 6 , wherein the medication treatment comprises one or more of statins, icosapent ethyl, bempedoic acid, rivaroxaban, aspirin, proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors, inclisiran, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, low-density lipoprotein (LDL) apheresis, or Lp(a) lowering medication.
8. The computer-implemented method of claim 6 , wherein the lifestyle treatment comprises one or more of increased exercise, aerobic exercise, anaerobic exercise, cessation of smoking, or change in diet.
9. The computer-implemented method of claim 6 , wherein the revascularization treatment comprises one or more of bypass grafting, stenting, or use of a bioabsorbable scaffold.
10. The computer-implemented method of claim 1 , wherein one or more of the first set of plaque parameters, second set of plaque parameters, first set of vascular parameters, or second set of vascular parameters is normalized to account for one or more of scanner type, image acquisition parameters, energy, gating, contrast, age of subject, subject body habitus, surrounding cardiac structure, or plaque type.
11. The computer-implemented method of claim 1 , wherein an increase in density of the one or more regions of plaque is indicative of a positive efficacy of the medical treatment.
12. The computer-implemented method of claim 11 , wherein the density of the one or more regions of plaque comprises radiodensity.
13. The computer-implemented method of claim 11 , wherein the density of the one or more regions of plaque comprises absolute density.
14. The computer-implemented method of claim 1 , wherein the first set of plaque parameters and the second set of plaque parameters further comprise a location of the one or more regions of plaque, the location of the one or more regions of plaque comprising one or more of myocardial facing, pericardial facing, bifurcation, trifurcation, proximal, mid, distal, main vessel, or branch vessel.
15. The computer-implemented method of claim 14 , wherein a change in location of a region of plaque from pericardial facing to myocardial facing is indicative of a positive efficacy of the medical treatment.
16. The computer-implemented method of claim 1 , wherein the volume of the one or more regions of plaque comprises one or more of absolute plaque volume or percent atheroma volume (PAV).
17. The computer-implemented method of claim 1 , wherein an increase in volume of the one or more regions of plaque between the first point in time and the second point in time is indicative of a negative efficacy of the medical treatment.
18. The computer-implemented method of claim 1 , wherein vascular remodeling comprises vascular remodeling of one or more coronary atherosclerotic lesions.
19. The computer-implemented method of claim 1 , wherein vascular remodeling comprises one or more directionality changes in remodeling, the one or more directionality changes in remodeling comprising one or more of outward, intermediate, or inward.
20. The computer-implemented method of claim 19 , wherein more outward remodeling between the first point in time and the second point in time is indicative of a negative efficacy of the medical treatment.
21. A system for tracking efficacy of a treatment for a plaque-based disease based on non-invasive medical image analysis, the system comprising:
one or more computer readable storage devices configured to store a plurality of computer executable instructions; and
one or more hardware computer processors in communication with the one or more computer readable storage devices and configured to execute the plurality of computer executable instructions in order to cause the system to:
access a first set of plaque parameters and a first set of vascular parameters associated with a subject, wherein the first set of plaque parameters and the first set of vascular parameters are derived from a first set of medical images of the subject comprising at least one axial image comprising one or more regions of plaque, wherein the one or more plaque parameters are determined automatically based at least in part by applying a machine learning algorithm to the accessed first set of medical images, wherein the first set of medical images of the subject is obtained non-invasively at a first point in time, wherein the first set of plaque parameters comprises density and volume of one or more regions of plaque derived from the first medical image of the subject obtained at the first point in time, and wherein the first set of vascular parameters comprises one or more of volume, diameter, area, length, location, or remodeling derived from the first set of medical images of the subject obtained at the first point in time;
generate a first characterized region of plaque, wherein generating the first characterized region of plaque comprises characterizing the one or more regions of plaque in the first set of medical images of the subject obtained at the first point in time as calcified plaque, non-calcified plaque, or low density non-calcified plaque based on the first set of plaque parameters;
access a second set of medical images of the subject, wherein the second set of medical images of the subject is obtained non-invasively at a second point in time after the subject is treated with a treatment, the second point in time being later than the first point in time, wherein the second set of medical images of the subject comprises at least one axial image comprising the one or more regions of plaque;
identify the one or more regions of plaque from the second set of medical images;
determine a second set of plaque parameters and a second set of vascular parameters associated with the subject by analyzing the one or more regions of plaque identified from the second set of medical images, the second set of plaque parameters determined based at least in part on graphical identification of vessel wall and lumen wall from the second set of medical images, wherein the second set of plaque parameters comprises density and volume of the one or more regions of plaque derived from the second medical image of the subject obtained at the second point in time, and wherein the second set of vascular parameters comprises one or more of vascular volume, diameter, area, length, location, or remodeling derived from the second set of medical images of the subject obtained at the second point in time;
generate a second characterized region of plaque, wherein generating the first characterized region of plaque comprises characterizing the one or more regions of plaque in the second set of medical images of the subject obtained at the second point in time as calcified plaque, non-calcified plaque, or low density non-calcified plaque based on the first set of plaque parameters;
analyze one or more changes between the first characterized region of plaque and the second characterized region of plaque;
analyze one or more changes between the first set of vascular parameters and the second set of vascular parameters; and
generate a graphical representation of tracking progression of the plaque-based disease based at least in part on the analyzed one or more changes between the first characterized region of plaque and the second characterized region of plaque and the analyzed one or more changes between the first set of vascular parameters and the second set of vascular parameters, wherein the generated graphical representation of tracking progression of the plaque-based disease is configured to be used to determine efficacy of the treatment, wherein the determined efficacy of the treatment is configured to be used to determine whether to change the treatment for the subject.
22. The system of claim 21 , wherein the graphical representation of tracking progression of the plaque-based disease is generated on one or more of a per-subject, per-vessel, per-segment, or per-lesion basis.
23. The system of claim 21 , wherein the system is further caused to determine the efficacy of the treatment based at least in part on the progression of the plaque-based disease.
24. The system of claim 23 , wherein the system is further caused to generate a further proposed treatment based at least in part on the efficacy of the treatment determined based on the tracked progression of the plaque-based disease.
25. The system of claim 21 , wherein the treatment comprises one or more of a medication treatment, lifestyle treatment, or revascularization treatment.
26. The system of claim 25 , wherein the medication treatment comprises one or more of statins, icosapent ethyl, bempedoic acid, rivaroxaban, aspirin, proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors, inclisiran, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, low-density lipoprotein (LDL) apheresis, or Lp(a) lowering medication, wherein the lifestyle treatment comprises one or more of increased exercise, aerobic exercise, anaerobic exercise, cessation of smoking, or change in diet, and wherein the revascularization treatment comprises one or more of bypass grafting, stenting, or use of a bioabsorbable scaffold.
27. The system of claim 21 , wherein one or more of the first set of plaque parameters, second set of plaque parameters, first set of vascular parameters, or second set of vascular parameters is normalized to account for one or more of scanner type, image acquisition parameters, energy, gating, contrast, age of subject, subject body habitus, surrounding cardiac structure, or plaque type.
28. The system of claim 21 , wherein the density of the one or more regions of plaque comprises radiodensity.
29. The system of claim 21 , wherein the density of the one or more regions of plaque comprises absolute density.
30. The system of claim 21 , wherein an increase in density of the one or more regions of plaque is indicative of a positive efficacy of the medical treatment.